Biotechnology Corporate News

• Artificial Intelligence-Based Technology Yielding Positive Results in Drug Discovery Collaborations (May 6)
  
• Sirona Biochem Raises $2.4 Million To Date; Extends Warrants (May 3)
  
• CO2 Solutions Host Prime Minister Harper for Carbon Capture Grant Announcement (May3)
  
• ADDITIONAL U.S. PATENTS FOR LEAD CANCER DRUG CANDIDATE
  STRENGTHEN CRITICAL OUTCOME’S INVESTMENT PROPOSITION (April 26)
  
• VIDO celebrates certification of the International Vaccine Centre at the U of S (April 23)
  
• Merck Invests in Pan-Canadian Life Sciences Research Innovation Sector (April 22)
  
• Asmacure Dosed First Subjects With ASM-024 Dry Powder For Inhalation (April 15)
  
• COTI Provides Important Update on AML Program (April 9)
  
• Cynapsus Therapeutics Completes $6 Short Form Prospectus Offering (March 15)
  
• CO2 Solutions Announces Agreement with Statoil (March 13)
  
• Neurodyn Inc. Key Patent Issues (March 11)
  
• Qu Biologics Launches Treatment Trial for Crohn's Disease (March 7)
  
• Vaccination of Cattle to Reduce Public Health Risk of E.coli 0157 Featured in teh Canadian Journal of Public Health (Feb.28)
  
• Critical Outcome Technologies Inc. Completes Financing (Jan.31)
  
• Immunovaccine Signs Agreement for Phase I/II Clinical Trial of DPX-0907 in Breast and Ovarian Cancer Patients (Jan.30)
  
• Alliance of Translational Research Centres Established to Accelerate Global Drug Development (Jan.21)
  
• Sirona Biochem Granted European Patent for Carbohydrate Chemistry Platform Technology (Jan.25)
  
• Bioniche Life Sciences Inc. Launches Two New Animal Health Products in Canada (Jan.24)
  
• CO2 Solutions Receives $4.7 Million from the Harper Government for Oil Sands Carbon Capture Project.  (Jan.24)
  
• Ontario Genomics Institute Invests in Validation of a Novel Protein Interaction Technology at the University of Toronto (Nov.1)
  
• Cynapsus Therapeutics' APL 130277 For Parkinson's Chosen As One Of The Top Ten Neurology Projects To Watch For 2012 (Oct.29)
  
• Anti-Cocaine Vaccine Combined with Immunovaccine’s DepoVax™ Shows Promise in Exploratory Study (Oct.24)
  
• Immunovaccine’s DPX-Survivac Cancer Vaccine Delivers Positive Results in Clinical Study (Oct.9)
  
• CRITICAL OUTCOME TECHNOLOGIES INC. ACHIEVES IMPORTANT
  MILESTONE FOR AML PROGRAM (Oct.9)
  
• CO2 Solutions Granted Broad U.S. Patent (Oct.3)
  
• Critical Outcome Technologies Inc. delivering podium presentation on new mechanism of Action Data for COTI-2 (Sept.28)
  
• Sirona Biochem Hires GrowthPoint Group (Sept 20)
  
• Critical Outcome Technologies Announces important new mechanism of action data for Coti-2 (Sept 20)
  
• Critical Outcome Technologies and Delmar Chemicals sign collaboration agreement (Sept 12)
  
• Indel Therapeutics Named Industry Partner for New Genomics Research Project  (Sept 11)
  
• Cynapsus Therapeutics Reports Second Quarter 2012 Financial Results and Recent Developments (Aug 29)
• Cynapsus Therapeutics Awarded Grant from the Michael J. Fox Foundation (Aug 8)
  
• Pfizer Canada Injects $4.5 Million into Public Research on Alzheimer's Disease (June 28)
  
• Zymeworks Receives Inaugural Biotech Rising Star Award at the 14th Annual C21 BioVentures Conference (May 25)
  
• Cynapsus Therapeutics Appoints Dr. Abraham Lieberman to Clinical Advisory Board (April 23)
  
• Therapure Announces Opening of Custom Biologics Manufacturing Wing (April 20)
  
• Immunovaccine Joins with Weill Cornell Medical College To Advance Anti-Cocaine Vaccine (March 12)
  
• Immunovaccine Grants Stock Options (March 9)
  
• iCo Therapeutics Appoints Douglas Janzen to Board of Directors (March 5)
  
• Loewen, Ondaatje, McCutcheon Initiates Independent Analyst Coverage on Cynapsus Therapeutics (March 5)
• OGI Invests in the Development of a Molecular Diagnostic to Monitor Patient Responses to Chemotherapy (March 1)
• Immunovaccine to Advance Biodefense Vaccines in a NIH Funded Study (February 14)
  
• BioTalent Canada Tool Offers Hope for Unemployed Manufacturing Workers in Kitchener Waterloo (February 8)
  
• John Helou named President of Pfizer Canada Inc. (February 8)
  
• Canadian Biotech Firms Look to Unemployed Manufacturing Workers to Fill Jobs (February 8)
  
• SemBioSys and Tasly Pharmaceutical to participate in the 5th Canada-China Business Forum and Signing Ceremony (February 8)
  
• Del Mar Pharmaceuticals to Present Pre-clinical Data Related to the Mechanism of VAL-083 at the AACR Annual Meeting in April 2012 (February 7)
  
• Quebec is first in Canada to provide access to innovative treatment, XGEVA (February 7)
  
• OncoGenex Pharmaceuticals to Present at Upcoming Investor Conferences (February 7)
  
• First and only treatment to extend survival for people with metastatic melanoma, the most deadly form of skin cancer, approved in Canada (February 7)
  
• Sanofi Pasteur moves national immunization strategy forward with new bar code technology (February 7)
  
• OncoGenex Pharmaceuticals to Present at Upcoming Investor Conferences (February 7)
  
• Del Mar Pharmaceuticals to Present Pre-clinical Data Related to the Mechanism of VAL-083 at the AACR Annual Meeting in April 2012 (February 7)
• COTI Identifies Phase 1 Oral Formulation Candidates for COTI-2 (February 2)
  
• Critical Outcome Technologies Inc. Identifies Phase 1 Oral Formulation Candidates for Coti-2 (February 2)
  
• Del Mar Pharmaceuticals Granted U.S. Orphan Drug Designation for VAL-083 for the Treatment of Glioma (February 2)
  
• PlantForm launches HIV antibody project (January 31)
  
• Cynapsus Therapeutics Announces Successful Human Volunteer Pilot Proof-of-Concept Results for APL-130277 (January 10)